Counting your chickens before they hatch. We still have not seen the data therefore we do not know what they outcome will be. If Alz fails, why would people think excellence will do any better? We ve had very small trials so far. Remember the avatar Trial didn’t show dose dependency. This Alz readout will make or break the companies stock price until excellence readout as the next catalyst in 2023.
News 
Market Data 
Discover 
